- Supported exchanges /
- F /
- 2PU.F
PULMATRIX INC. DL-0001 (2PU F) stock market data APIs
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
PULMATRIX INC. DL-0001 Financial Data Overview
| 1.92 | |
| 1.84 | |
| - | |
| 1.92 | |
| 1.83 | |
| 1.412-2.16 | |
| 7 050 K | |
| 3 652 K | |
| 11 392 K | |
| 0.999 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PULMATRIX INC. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 11 392 K
- EBITDA -11 142 000
- Earnings Per Share -2.76
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get PULMATRIX INC. DL-0001 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get PULMATRIX INC. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
